[Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
Tanczos
B T
BT
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitätsklinikum Charité, Campus Virchow-Klinikum, Medizinische Fakultät der Humboldt-Universität zu Berlin.
Baumgart
D C
DC
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000188:drug therapy*; D000069285:Infliximab; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D005765:Gastrointestinal Agents; D000069285:Infliximab